Search hospitals > Tennessee > Nashville
Tennessee Oncology
Claim this profileNashville, Tennessee 37203
Global Leader in Breast Cancer
Global Leader in Solid Tumors
Conducts research for Tumors
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Lung Cancer
246 reported clinical trials
14 medical researchers
Summary
Tennessee Oncology is a medical facility located in Nashville, Tennessee. This center is recognized for care of Breast Cancer, Solid Tumors, Tumors, Non-Small Cell Lung Cancer, Lung Cancer and other specialties. Tennessee Oncology is involved with conducting 246 clinical trials across 160 conditions. There are 14 research doctors associated with this hospital, such as Melissa Johnson, MD, Erika P Hamilton, Meredith A McKean, and David R. Spigel, MD.Area of expertise
1Breast Cancer
Global LeaderStage IV
HER2 negative
Stage III
2Solid Tumors
Global LeaderStage IV
Stage III
PIK3CA positive
Top PIs
Melissa Johnson, MDSarah Cannon Research Institute5 years of reported clinical research
Expert in Non-Small Cell Lung Cancer
Expert in Tumors
62 reported clinical trials
89 drugs studied
Erika P HamiltonSarah Cannon Research Institute4 years of reported clinical research
Expert in Breast Cancer
Expert in Ovarian Cancer
53 reported clinical trials
76 drugs studied
Meredith A McKeanSarah Cannon Research Institute1 year of reported clinical research
Expert in Solid Tumors
Expert in Tumors
34 reported clinical trials
66 drugs studied
David R. Spigel, MDTennessee Oncology3 years of reported clinical research
Expert in Non-Small Cell Lung Cancer
Expert in Tumors
29 reported clinical trials
54 drugs studied
Clinical Trials running at Tennessee Oncology
Breast Cancer
Non-Small Cell Lung Cancer
Cancer
Colorectal Cancer
Tumors
Solid Tumors
Lung Cancer
Pancreatic Cancer
Ovarian Cancer
Melanoma
Navicixizumab Combinations
for Advanced Breast Cancer
This is a study of navicixizumab monotherapy or in combination with paclitaxel or irinotecan in patients with advanced cancer. Patients will be enrolled into one of the following cancer cohorts: * Cohort A: CRC * Cohort B: Gastric and GEJ cancer * Cohort C: TNBC * Cohort D: Platinum-resistant/refractory epithelial ovarian, primary peritoneal, or fallopian tube cancer (ovarian cancer)
Recruiting2 awards Phase 221 criteria
Giredestrant + Hormone Therapy
for Early-Stage Breast Cancer
This trial is testing giredestrant, a medication given after initial treatment to prevent breast cancer from returning. It focuses on patients with a specific type of early-stage breast cancer that is hormone-driven and at higher risk of recurrence. Giredestrant works by blocking the hormone estrogen from helping cancer cells grow. Giredestrant has shown promise in previous studies.
Recruiting2 awards Phase 311 criteria
Tucatinib + Doxil
for Breast Cancer
This clinical trial is evaluating tucatinib in combination with Doxil in participants with human epidermal growth factor 2 positive (HER2+) locally advanced or metastatic breast cancer. The main goals of this study are to: * Learn how well the combination of tucatinib and Doxil works * Learn more about the side effects of the combination of tucatinib and Doxil
Recruiting1 award Phase 213 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Tennessee Oncology?
Tennessee Oncology is a medical facility located in Nashville, Tennessee. This center is recognized for care of Breast Cancer, Solid Tumors, Tumors, Non-Small Cell Lung Cancer, Lung Cancer and other specialties. Tennessee Oncology is involved with conducting 246 clinical trials across 160 conditions. There are 14 research doctors associated with this hospital, such as Melissa Johnson, MD, Erika P Hamilton, Meredith A McKean, and David R. Spigel, MD.